详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Recent progress in DNA methyltransferase inhibitors as anticancer agents

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, Innovation Center of Nursing Research, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, China [2]Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China [3]School of Physical Science and Technology, Electron Microscopy Center of Lanzhou University, Lanzhou University, Lanzhou, China [4]Science and Technology Department, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China

出处：

DOI：

ISSN：

关键词： epigenetic DNA methylation DNA methyltransferase DNA methyltransferase inhibitor tumor immunotherapy

摘要：

DNA methylation mediated by DNA methyltransferase is an important epigenetic process that regulates gene expression in mammals, which plays a key role in silencing certain genes, such as tumor suppressor genes, in cancer, and it has become a promising therapeutic target for cancer treatment. Similar to other epigenetic targets, DNA methyltransferase can also be modulated by chemical agents. Four agents have already been approved to treat hematological cancers. In order to promote the development of a DNA methyltransferase inhibitor as an anti-tumor agent, in the current review, we discuss the relationship between DNA methylation and tumor, the anti-tumor mechanism, the research progress and pharmacological properties of DNA methyltransferase inhibitors, and the future research trend of DNA methyltransferase inhibitors.Copyright © 2022 Zhang, Wang, Li, Lei, Xiang, Ouyang, Wang and Yang.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区药学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区药学

第一作者：

第一作者机构： [1]State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, Innovation Center of Nursing Research, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, China [2]Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China

共同第一作者：

通讯作者：

通讯机构： [1]State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, Innovation Center of Nursing Research, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, China [4]Science and Technology Department, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Targeting epigenetic modifications in Parkinson's disease therapy [2]CRC-EBD: Epigenetic Biomarker Database for Colorectal Cancer [3]Multiple network algorithm for epigenetic modules via the integration of genome-wide DNA methylation and gene expression data. [4]KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells [5]Mapping the epigenetic modifications of DNA and RNA. [6]KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells [7]Multiple network algorithm for epigenetic modules via the integration of genome-wide DNA methylation and gene expression data. [8]Epigenetic modifications promote the expression of the orphan nuclear receptor NR0B1 in human lung adenocarcinoma cells [9]Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer [10]Management of triple-negative breast cancer by natural compounds through different mechanistic pathways